Posted on by

CJC-1295: what hormone studies can tell us

This educational article discusses selected studies rather than providing a complete clinical review. It does not recommend personal use or provide treatment instructions.

A hormone level can change without proving that a person becomes healthier, stronger or more energetic. Understanding that distinction is central to reading the research on CJC-1295.

CJC-1295 was investigated as a long-acting analogue of growth hormone-releasing hormone, or GHRH. In a 2006 paper, researchers examined its effects on growth hormone and insulin-like growth factor I, usually shortened to IGF-I. The study asked how the compound behaved in the body and how those hormone measurements responded. Teichman and colleagues, 2006 [1].

What the human study measured

The publication reported two randomised, double-blind, placebo-controlled studies lasting 28 and 49 days. Participants were healthy adults aged 21 to 61. Researchers observed sustained increases in GH and IGF-I, and reported no serious adverse reactions in those studies.

That is evidence of biological activity in a defined setting. It is not a demonstration of improved athletic performance, longer life or an effective treatment for a diagnosed hormone deficiency. Nor does a short study establish the safety of prolonged use. Those broader questions require their own relevant endpoints, populations and follow-up. The original clinical study [1].

A laboratory number is not the final outcome

A useful reading exercise is to separate three statements: a compound changed a measured marker; that change produced a meaningful benefit; and the benefit outweighed the risks. These are different claims. Evidence for the first does not, by itself, complete the argument for the other two.

For example, if an article promises better physical function, look for actual measurements of function rather than a hormone graph alone. If it promises long-term benefits, check whether the observation period was long enough to investigate them.

Why identity and formulation deserve attention

Before applying any paper to another preparation, check that the exact substance and formulation match. A shared name or abbreviation is not a substitute for that comparison.

Analytical testing also asks several separate questions: identity concerns what a substance is; an assay concerns how much is present; impurity testing concerns other components. FDA specifications guidance treats these as distinct attributes. A single result should not be stretched into an answer to all three. FDA specifications guidance [2].

The FDA separately flags limited clinical data and potential safety concerns for compounded CJC-1295, including immune reactions and reported serious events involving increased heart rate and systemic vasodilation. This does not contradict the earlier trial: different evidence can reveal risks beyond one study’s observations. FDA safety assessment [3].

The most accurate summary is therefore specific: CJC-1295 has been studied for its hormonal effects, but hormonal activity should not be rewritten as a general promise of better health.

A note on testing

Three questions should remain separate: What was in the sample? What happened in the experiment? What has been established about use in people?

Analytical tests address defined properties of a sample. For example, identity, strength and impurities are distinct categories in drug-quality testing. FDA testing overview [4]. A test report should therefore be read for its actual scope, not treated as an all-purpose quality or safety certificate.

Endotoxin testing is another separate question: it concerns bacterial components that can cause inflammatory reactions. It does not provide the same information as a test for living microorganisms. FDA endotoxin background [5].

No supplier reports were audited for these articles, and no claims are made about which tests a particular commercial product has passed. These articles explain research; they do not certify products or establish suitability for human use.

Eternal Peptides Wholesale publishes batch-specific Janoshik Analytical reports in its certificate of analysis library, so the documentation for a listed batch can be read alongside the evidence discussed in this article.

References and bibliography

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. 2006. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. 91(3):799-805. doi:10.1210/jc.2005-1536.
  2. U.S. Food and Drug Administration / International Council for Harmonisation. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Accessed 27 September 2026.
  3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 27 September 2026.
  4. U.S. Food and Drug Administration. Drug Quality Sampling and Testing Programs. Accessed 27 September 2026.
  5. U.S. Food and Drug Administration. 1985. Bacterial Endotoxins/Pyrogens. Accessed 27 September 2026.